Skip to main content

UPM Biomedicals chooses the Basel Area as European bridgehead

| News

UPM Biomedicals chooses the Basel Area as European bridgehead


UPM Biomedicals is opening a lab on the Main Campus of Switzerland Innovation Park Basel Area. The Finnish company specializes in nanofibrillar cellulose products for life sciences and medical applications. It plans to use the Basel Area as its base for operations in continental Europe.

Delegates and staff of UPM Biomedicals at the opening event in the Switzerland Innovation Park Basel Area (image: UPM Biomedicals)

UPM Biomedicals recently opened a site on the Main Campus of Switzerland Innovation Park Basel Area in Allschwil in the canton of Basel-Landschaft. The Finnish company is a division of the international UPM Group, which has 17,200 employees. It specializes in renewable alternatives to fossil materials and operates in numerous sectors.

UPM Biomedicals manufactures products for life sciences and medical applications based on its nanofibrillar cellulose technology made from birch wood pulp, which was launched and patented in 2014. The company’s current portfolio is centered around four main product categories: GrowDex – hydrogels for 3D cell culture; GrowDase, an enzyme to recover cells from GrowDex for downstream processing; GrowInk, bioinks for 3D bioprinting; and FibDex, a dressing for wound care.

Becoming part of Basel Area’s life sciences community

Basel Area Business & Innovation, the investment and innovation promotion agency, convinced UPM Biomedicals of the Basel Area’s benefits as a location and supported them in setting up business in the area. Among others, it introduced the company to Switzerland Innovation Park Basel Area and other real estate opportunities.

According to a statement, the Basel Area is a “new bridgehead” for UPM Biomedicals: “Arriving in the Basel Area, one of the most dynamic life sciences clusters in the world, means that we are close to our customers in continental Europe,” commented Johana Kuncová-Kallio, Director of UPM Biomedicals, in the statement. “We gain access to the local talent pool and become part of the life sciences community in the Basel Area.”

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

Nouscom secures 67.5 million euros in financing

Biotech company Nouscom has raised 67.5 million euros in a series C financing round. The Basel-based firm intends to use...
Read More

Celebrating six months of innovation: i4Challenge accelerator New Ideas 2022/2023

On the 5th of July 2023, the 3rd iteration of the i4Challenge accelerator program New Ideas came to its conclusion....
Read More

How open innovation in healthtech hubs is fueling the rise of digital healthcare

How the ever-increasing uptake of digital solutions is enhancing patient engagement, increasing access to care and lowering the cost of...
Read More

Paradigm shift in pain management

Pain is a crucial sensation for survival, but it can also drive us to depression and long-term suffering if not...
Read More

BOOM Summit in Basel accelerates health technology

The BOOM Summit at Messe Basel in April 2024 will be a completely new kind of healthcare conference. The first...
Read More

Investors stump up 3.7 million Swiss francs in Onena Medicines

Onena Medicines has secured an investment of 3.7 million Swiss francs. The portfolio company of the biotech startup incubator BaseLaunch...
Read More

Do you have a question? We'd like to hear from you.